Sol-Gel Technologies (SLGL)
NASDAQ:SLGL
Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$73.87
-$0.16(-11.43%)
At close: 4:00 PM EST
$73.87
-$0.16(-11.43%)
Day’s Range― - ―
52-Week Range$6.91 - $97.97
Previous CloseN/A
Volume503.92K
Average Volume (3M)16.66K
Market Cap
$240.07M
Enterprise Value$198.26M
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Jul 30, 2026EPS Estimate
-3.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume26,975
30 Day Avg. Volume16,656
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue30.23
Enterprise Value/Gross Profit-19.69
Enterprise Value/Ebitda-12.07
Forecast
1Y Price Target
$184.00Price Target Upside149.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-11.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Valuation UpgradeAnalyst's higher price target after revising commercial assumptions reflects increased confidence in SGT-610's market uptake and could support positive investor sentiment.
First-in-class PotentialApproval of SGT-610 would establish the first preventive therapy for new basal cell carcinoma lesions in Gorlin syndrome, creating a clear first-mover commercial advantage.
Market Expansion OpportunityPotential approval in high-frequency basal cell carcinoma could substantially expand the addressable market and provide upside beyond the current valuation assumptions.
Bears Say
Financing And Dilution RiskPossibility of dilution to fund ongoing trials presents downside risk to shareholders if additional capital is required.
Pivotal Trial RiskFailure of the SGT-610 pivotal trial would materially reduce the chance of approval and likely trigger a negative re-rating of the stock.
Program DiscontinuationDiscontinuation of the SGT-210 program after negative study results highlights clinical development risk and raises concerns about pipeline durability.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $6.91 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $240.07M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Jul 30, 2026 which is in 44 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on May 08, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of -$2.86 by $4.17.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -3.33.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,268,991 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of $1.31 in its last earnings report, beating expectations of -$2.86. Following the earnings report the stock price went up 1.898%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$184.00 (149.09% Upside)
$184.00 (149.09% Upside)
Insider Transactions
Bought Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
682.16%
12-Months-Change
Fundamentals
Return on Equity
-3.17%
Trailing 12-Months
Asset Growth
116.35%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$184.00
▲(149.09% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
15.45% Insiders
0.04% Mutual Funds
36.17% Other Institutional Investors
48.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---